BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sensimed to Actively Participate in the Coming Glaucoma 360 Conference and at the American Glaucoma Society in the USA


1/22/2013 9:08:03 AM

LAUSANNE, SWITZERLAND--(Marketwire - January 22, 2013) - Sensimed AG, the developer of a revolutionary contact lens (the SENSIMED Triggerfish®) for the continuous monitoring of fluctuations in intraocular pressure (IOP) to facilitate the management of glaucoma, announced today that the company will participate in two major glaucoma meetings taking place in San Francisco in February 2013.

Sensimed is proud to present its breakthrough technology at the Glaucoma 360 New Horizons Forum being held on Friday, February 1st, 2013 at the Palace Hotel, in San Francisco. The conference presented by the Glaucoma Research Foundation brings together key clinical, industry, financial and regulatory leaders in a unique exchange on research innovation and advances in glaucoma treatment. Globally, glaucoma is a leading cause of preventable blindness.

In addition, the company will present 4 scientific abstracts at the upcoming American Glaucoma Society (AGS) meeting from February 28th to March 3rd 2013 in San Francisco. The abstracts will be reporting on the use of the SENSIMED Triggerfish® in clinical studies.

FROM DEVICE TO KNOWLEDGE -- Sensimed AG, a Swiss company, has developed a non-invasive soft contact lens-based solution, the SENSIMED Triggerfish that revolutionizes glaucoma management by providing continuous 24 hour intraocular pressure (IOP) profiles as well as modeling and analysis of IOP patterns. The 24 hour IOP profiles, centralized on a registry together with patient and treatment information, are processed by powerful modeling and learning algorithms identifying pathological patterns that can be used to differentiate indication and to personalize treatment. Sensimed is directly positioned at the convergence between devices, treatment and information. The company believes that this global knowledge-building approach will enable ophthalmologists to better improve management of patients with potentially progressive glaucomatous disease.

For further information about Sensimed see: www.sensimed.ch

About Glaucoma Research Foundation
Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America's oldest and most experienced nonprofit dedicated solely to its mission: to prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Celebrating its 35th anniversary in 2013, Glaucoma Research Foundation has invested more than $40 million to advance essential research and education programs.

More information is available at www.glaucoma.org/about.

For further information about the AGS see: www.americanglaucomasociety.net

The SENSIMED Triggerfish® is not approved for sale in the USA.

Sensimed at Glaucoma 360 and AGS: http://hugin.info/142388/R/1672101/543754.pdf


Sensimed AG
Jean-Marc Wismer
CEO
jean-marc_wismer@sensimed.ch
Tel: +41 21 621 9191




Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES